The short version of counter-ion fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-12 and is reviewed periodically as new material appears.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Shiga toxins are a family of related toxins with two major groups, Stx1 and Stx2, expressed by genes considered to be part of the genome of lambdoid prophages. The toxins are named after Kiyoshi Shiga, who first described the bacterial origin of dysentery caused by Shigella dysenteriae. Shiga-like toxin (SLT) is a historical term for similar or identical toxins produced by Escherichia coli. The most common sources for Shiga toxin are the bacteria S. dysenteriae and some serotypes of Escherichia coli (shigatoxigenic or STEC), which include serotypes O157:H7, and O104:H4. Microbiologists use many terms to describe Shiga toxin and differentiate more than one unique form. Many of these terms are used interchangeably.
Growth in these areas remained slow during the middle 1990s, in spite of the backing of lead replacement by the United States federal government, but intensified around 2005. This resulted in a rapid and continuing increase in price.
=== Subspecialties === The field of psychiatry has many subspecialties that require additional training and certification by the American Board of Psychiatry and Neurology (ABPN). Such subspecialties include:
Sources: en.wikipedia.org
During the warm months of June, July, and August, typical high temperatures are 20 to 26 °C (68 to 79 °F). However, during heat waves (which can occur between May and September), daytime high temperatures often exceed 30 °C (86 °F), sometimes for a week or two. In the winter, average temperatures normally fall to approximately −10 °C (14 °F). Nevertheless, most winters have warmer periods with daytime temperatures rising above 0 °C (32 °F), as well as cooler periods with night temperatures falling below −20 °C (−4 °F). These periods usually last a week or two. The growing season in Moscow normally lasts for 156 days, usually around 1 May to 5 October. The highest temperature ever recorded in Moscow was 38.2 °C (100.8 °F) at the VVC weather station, as well as 39.0 °C (102.2 °F) in the center of Moscow and at Domodedovo airport; this temperature occurred on 29 July 2010, during the unusual 2010 Northern Hemisphere heat waves. Record high and average temperatures were recorded in January, March, April, May, June, July, August, November, and December of 2007–2022. The average July temperature from 1991 to 2020 is 19.7 °C (67.5 °F). The lowest temperature ever recorded was −42.1 °C (−43.8 °F) in January 1940. Snow, which is present for about five months a year, often begins to fall in mid-October; snow cover persists in late November and melts at the end of March. On average, Moscow receives 1731 hours of sunshine per year, ranging between 8% in December and 52% from May to August. This annual variation is due to convective cloud formation.
As with the chemical antioxidants, cells are protected against oxidative stress by an interacting network of antioxidant enzymes. Here, the superoxide released by processes such as oxidative phosphorylation is first converted to hydrogen peroxide and then further reduced to give water. This detoxification pathway is the result of multiple enzymes, with superoxide dismutases catalysing the first step and then catalases and various peroxidases removing hydrogen peroxide. As with antioxidant metabolites, the contributions of these enzymes to antioxidant defenses can be hard to separate from one another, but the generation of transgenic mice lacking just one antioxidant enzyme can be informative.
== History == April 2016: initiation of Phase 2b trial December 2017: initiation of JADE Mono-1 Phase 3 trial May 2018: Results of Phase 2b trial posted October 2019: Results of Phase 3 trial presented June 2020: Results of second Phase 3 trial published The US Food and Drug Administration (FDA) approved abrocitinib based on evidence from three controlled clinical trials enrolling a total of 1615 participants supporting efficacy and safety. Two of the trials enrolled participants twelve years of age and older with moderate-to-severe atopic dermatitis and one trial enrolled adults with moderate-to-severe atopic dermatitis. The trials were conducted at multiple sites in 18 countries (i.e., United States, Canada, Australia, Mexico, Chile, Great Britain, Poland, Germany, Bulgaria, Hungary, Czech Republic, Latvia, Slovakia, Spain, Italy, Japan, Korea, Taiwan). In addition, safety analyses were performed on the combined results of these 3 controlled clinical trials and one additional controlled study in a total of 1,540 participants. All three trials evaluated two doses of abrocitinib: 100 mg and 200 mg. The monotherapy trials were identically designed, 16-week, randomized, multicenter, double-blind, placebo-controlled, parallel group, phase 3 trials. Trial-AD-3 with concomitant background therapy was a 24-week, multicenter, randomized, double-blind, active-comparator (dupilumab) and placebo-controlled, phase 3 trial.
Sources: en.wikipedia.org
=== Solid state work === Redfield's NMR career began with work on solids, like metals and superconductors. This work later proved to be useful in the study of the physical and motional relationships between protons in large biological molecules, called macromolecules.
One of the first Norman mercenaries to serve as a Byzantine general was Hervé in the 1050s. By then, however, there were already Norman mercenaries serving as far away as Trebizond and Georgia. They were based at Malatya and Edessa, under the Byzantine duke of Antioch, Isaac Komnenos. In the 1060s, Robert Crispin led the Normans of Edessa against the Turks. Roussel de Bailleul even tried to carve out an independent state in Asia Minor with support from the local population in 1073, but he was stopped in 1075 by the Byzantine general and future emperor Alexius Komnenos. Some Normans joined Turkish forces to aid in the destruction of the Armenian vassal-states of Sassoun and Taron in far eastern Anatolia. Later, many took up service with the Armenian state further south in Cilicia and the Taurus Mountains. A Norman named Oursel led a force of "Franks" into the upper Euphrates valley in northern Syria. From 1073 to 1074, 8,000 of the 20,000 troops of the Armenian general Philaretus Brachamius were Normans—formerly of Oursel—led by Raimbaud. They even lent their ethnicity to the name of their castle: Afranji, meaning "Franks". The known trade between Amalfi and Antioch and between Bari and Tarsus may be related to the presence of Italo-Normans in those cities while Amalfi and Bari were under Norman rule in Italy. Several families of Byzantine Greece were of Norman mercenary origin during the period of the Comnenian Restoration, when Byzantine emperors were seeking out western European warriors.
The enzyme α-carbonic anhydrase (CA) plays a vital role in regulating inorganic carbon balance within coral cells. It catalyzes two reversible reactions: the hydration of carbon dioxide (CO2) into bicarbonate (HCO−3) and a proton (H+), and the dehydration of bicarbonate back into CO2 and a proton. Through these interconversions, α-carbonic anhydrase facilitates the efficient transport and supply of dissolved inorganic carbon for both photosynthesis and calcification, maintaining the delicate equilibrium between CO2 and bicarbonate required for coral metabolic and skeletal processes. Ocean acidification poses a major threat to coral calcification by reducing the availability of carbonate ions (CO2−3), which are essential for forming calcium carbonate (CaCO3) skeletons. Under increasingly acidified conditions, corals must expend more energy to pump protons (H+) out of the calcifying space in order to maintain favorable conditions for mineral deposition. This heightened energetic demand compromises coral growth and skeletal density, resulting in weaker and more brittle structures. Consequently, coral reefs become more susceptible to physical damage from waves and storms, as well as less resilient to other environmental stressors.
A broad-spectrum chemokine inhibitor (BSCI), also termed chemotide or somatotaxin, is a type of experimental anti-inflammatory drug that inhibits the action of the pro-inflammatory proteins chemokines. Radiolabeling experiments performed by Dr. David Fox, University of Warwick, demonstrated the ability of the BSCI to bind and antagonize the somatostatin receptor 2 (SSTR2). This is a display of functional selectivity at the SSTR2 receptor. Functional selectivity is the effect of one ligand having one agonism when bound to the receptor and another ligand having a different agonism at that same receptor.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
Dry lyophilized powder tolerates short ambient exposure during handling and shipping. Long-term room-temperature storage is not recommended because moisture uptake and slow degradation can occur over months. Storage at minus twenty degrees Celsius is the common practice for extended periods.
Typical entries list appearance, identity by mass spectrometry, purity by chromatography, water or moisture content, and residual counter-ion. Some certificates also report microbial limits and endotoxin for materials intended for laboratory use. The reported methods and acceptance ranges vary between suppliers.
The peptide is often supplied as an acetate or trifluoroacetate salt, and the counter-ion affects solubility, weight-per-mole calculations, and compatibility with cell assays. Trifluoroacetate can be undesirable in some biological experiments. Knowing the salt form is necessary for accurate concentration determination.